Institut Jules Bordet

Running trials

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· Source

• Not yet recruiting

  Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.

  NCT07294430· Phase 2· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Recruiting

  A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours

  2025-521164-36-00· Phase 1/2· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Source

• Recruiting

  A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

  NCT07693751· Phase 1/2· Source

• Not yet recruiting

  Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy

  2025-523575-36-00· Phase 2· Source

• Recruiting

  Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

  NCT06990061· Source

• Recruiting

  Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma

  NCT07674498· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

  NCT07531095· Phase 1· Source

• Recruiting

  Radiopharmaceutical Treatment of Advanced Kidney Cancer

  NCT06783348· Phase 2· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Source

• Recruiting

  LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor

  NCT04939610· Phase 2· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· Phase 2/3· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Recruiting

  Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

  NCT07281833· Phase 3· Source

• Recruiting

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· Phase 1/2· Source

• Recruiting

  A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)

  2024-511392-15-00· Phase 3· Source

• Recruiting

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· Phase 2· Source

• Recruiting

  Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

  2024-514693-47-01· Phase 4· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Recruiting

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Recruiting

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· Phase 3· Source

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· Source

• Recruiting

  Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

  2023-510356-23-00· Phase 1· Source

• Recruiting

  Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

  NCT06918002· Phase 3· Source

• Recruiting

  A First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer

  2024-518360-13-00· Phase 1· Source

• Recruiting

  BreAK CRC (001) trial

  2024-512011-45-00· Phase 1/2· Source

• Recruiting

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· Phase 3· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Active, not recruiting

  Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Phase 2· Source

• Recruiting

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· Phase 3· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Source

• Recruiting

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer18 recruiting
• Metastatic breast cancer17 recruiting
• Colorectal cancer16 recruiting
• Pancreatic cancer9 recruiting
• Endometrial cancer7 recruiting
• Gastric and esophageal cancer7 recruiting
• Head and neck cancer7 recruiting
• Ovarian cancer6 recruiting
• Acute myeloid leukemia5 recruiting
• Multiple myeloma5 recruiting
• Prostate cancer5 recruiting
• Triple-negative breast cancer5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Kidney cancer4 recruiting
• Bladder cancer3 recruiting
• Melanoma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

  NCT06595563· Phase 2· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Source

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

  NCT06632951· Phase 2· Source

• Completed

  TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines in Adults With ER+ Advanced or Metastatic Breast Cancer, Sub-study C (ARV-471 and Samuraciclib)

  NCT06125522· Phase 1/2· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Source

• Completed

  A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

  NCT05487248· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Source

• Completed

  PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)

  NCT05880446· Source

• Completed

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· Phase 2· Source

• Active, not recruiting

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· Phase 2· Source

• Completed

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· Phase 2· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Source

• Terminated

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· Phase 2· Source

• Active, not recruiting

  A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

  NCT05307705· Phase 1· Source

• Active, not recruiting

  A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

  NCT05143970· Phase 1· Source

• Active, not recruiting

  A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

  NCT05091567· Phase 3· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Completed

  Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

  NCT04925284· Phase 1· Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Phase 1/2· Source

• Completed

  Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

  NCT04697628· Phase 3· Source

• Completed

  Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)

  2024-511140-37-00· Phase 2· Source

• Completed

  Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)

  NCT04797780· Phase 3· Source

• Completed

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· Phase 2· Source

• Active, not recruiting

  A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast cancer

  NCT03975647· Phase 3· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Source

• Completed

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  NCT03993912· Phase 3· Source

• Active, not recruiting

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· Phase 3· Source

• Terminated

  A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

  NCT03901469· Phase 2· Source

• Active, not recruiting

  Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

  NCT03937219· Phase 3· Source

• Completed

  A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

  NCT03783442· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· Phase 3· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Source

• Active, not recruiting

  A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

  NCT03504397· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· Phase 3· Source

• Completed

  A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

  NCT02060188· Phase 2· Source